Humana Files 8-K for Regulation FD Disclosure on Feb 5, 2024

TL;DR

**Humana just filed an 8-K for Regulation FD, expect new material info soon.**

AI Summary

Humana Inc. filed an 8-K on February 5, 2024, under Regulation FD Disclosure, indicating that they are making a public disclosure of material non-public information. This filing, while not detailing the specific information, signals that Humana is proactively sharing important news with investors. For shareholders, this means new information that could impact the stock price is being released, and they should look for subsequent announcements or details to understand the full implications.

Why It Matters

This filing signals that Humana Inc. is disclosing material information to the public, which could influence investor sentiment and the company's stock performance. Investors should anticipate further details to understand the nature of this disclosure.

Risk Assessment

Risk Level: low — This 8-K is a procedural filing indicating a disclosure, not a specific event, so the immediate risk is low.

Analyst Insight

A smart investor would monitor Humana's news releases and SEC filings closely for the specific details of the Regulation FD disclosure, as this information could impact the stock's valuation.

Key Players & Entities

• Humana Inc. (company) — the registrant filing the 8-K
• February 5, 2024 (date) — date of earliest event reported and filing date
• Regulation FD Disclosure (other) — the item information for the 8-K

Forward-Looking Statements

• Humana will release specific details regarding the material non-public information disclosed under Regulation FD. (Humana Inc.) — high confidence, target: within 1-3 business days

FAQ

From the Filing

0000049071-24-000009.txt : 20240205 0000049071-24-000009.hdr.sgml : 20240205 20240205070057 ACCESSION NUMBER: 0000049071-24-000009 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240205 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20240205 DATE AS OF CHANGE: 20240205 FILER: COMPANY DATA: COMPANY CONFORMED NAME: HUMANA INC CENTRAL INDEX KEY: 0000049071 STANDARD INDUSTRIAL CLASSIFICATION: HOSPITAL & MEDICAL SERVICE PLANS [6324] ORGANIZATION NAME: 02 Finance IRS NUMBER: 610647538 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-05975 FILM NUMBER: 24593923 BUSINESS ADDRESS: STREET 1: 500 W MAIN ST CITY: LOUISVILLE STATE: KY ZIP: 40202 BUSINESS PHONE: 5025801000 MAIL ADDRESS: STREET 1: 500 W. MAIN ST CITY: LOUISVILLE STATE: KY ZIP: 40202 FORMER COMPANY: FORMER CONFORMED NAME: EXTENDICARE INC DATE OF NAME CHANGE: 19740404 FORMER COMPANY: FORMER CONFORMED NAME: HERITAGE HOUSE OF AMERICA INC DATE OF NAME CHANGE: 19671129 8-K 1 hum-20240205.htm 8-K hum-20240205 0000049071 false 0000049071 2024-02-05 2024-02-05 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K                  CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported):  February 5, 2024 (February 5, 2024) Humana Inc. (Exact name of registrant as specified in its charter) Delaware 1-5975 61-0647538 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 500 West Main Street Louisville , KY 40202 (Address of principal executive offices, including zip code) 502 - 580-1000 (Registrant’s telephone number, including area code) (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock HUM New York Stock Exchange Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company   ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐ Item 7.01 Regulation FD Disclosure. On Wednesday, January 31, 2024, after the stock market closed, the Centers for Medicare and Medicaid Services (CMS) issued its preliminary 2025 Medicare Advantage and Part D payment rates and proposed policy changes (collectively, the Advance Notice). CMS has invited public comment on the Advance Notice before publishing final rates on April 1, 2024 (the Final Notice). In the Advance Notice, CMS estimates Medicare Advantage plans across the sector will, on average, experience a 0.16 percent decrease in benchmark funding based on proposals included therein. As indicated by CMS, its estimate excludes the impact of fee-for